Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

State of Alaska Department of Revenue lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.6% in the fourth quarter, HoldingsChannel reports. The fund owned 21,325 ...

Find out if it's safe to drink alcohol during your Ozempic treatment, whether alcohol raises the risk of any sides effects, ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.